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Effectiveness of antipsychotics used in first-
episode psychosis: a naturalistic cohort study
Richard Whale, Michael Harris, Gail Kavanagh, Vijitha Wickramasinghe, Christopher I. Jones,
Steven Marwaha, Ketan Jethwa, Nirmalan Ayadurai and Andrew Thompson
Background
One year of antipsychotic treatment from symptom remission
is recommended following a first episode of psychosis (FEP).
Aims
To investigate the effectiveness of commonly used
antipsychotic medications in FEP.
Method
A retrospective cohort study of naturalistic treatment of
patients (N=460) accepted by FEP services across seven UK
sites. Treatment initiation to all-cause discontinuation
determined from case files.
Results
Risk of treatment discontinuation is greatest within 3 months of
treatment initiation. Risperidone had longest median survival
time. No significant differences were observed in time to
discontinuation between commonly used antipsychotics on
multivariable Cox regression analysis. Poor adherence and
efficacy failure were the most common reasons for
discontinuation.
Conclusions
Effectiveness differences appear not to be a current reason for
antipsychotic choice in FEP. Adherence strategies and
weighing up likely adverse effects should be the clinical focus.
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The efficacy of antipsychotic medication for the treatment of acute
psychotic episodes and preventing subsequent relapse has been
clearly established in randomised controlled trials.1,2 Studies of
relative efficacy between medications, when combined by network
meta-analysis to enable ranking of effect, demonstrate some
differences between medications, such as grouping the efficacy of
clozapine, olanzapine, amisulpride and risperidone above other
antipsychotics.3 Such efficacy studies are most commonly under-
taken in chronic stage illness samples however. Studies of
antipsychotic efficacy conducted specifically in first-episode psy-
chosis (FEP) and early episode samples generally show fewer
differences between existing licenced medications,4–6 possibly
because efficacy of antipsychotics in treating positive symptoms
is overall greater in treatment naϊve psychosis. Adverse effects
appear more likely in treatment naϊve samples however,7 which
combined with other factors varying between antipsychotic
medications3 may suggest that differences in treatment effective-
ness could be more evident in FEP than efficacy differences.
Outcomes of naturalistic effectiveness studies in FEP may
importantly inform optimal clinical practice beyond the poten-
tially unrepresentative setting of the randomised efficacy trial.8
All-cause time to treatment discontinuation has been accepted as
a proxy measure of medication effectiveness, incorporating measure
of overall tolerability of themedication, views and judgements of the
clinician and patient and clinical efficacy.9,10 Pragmatic studies in
chronic schizophrenia samples of all-cause time to discontinuation
have demonstrated benefit of clozapine over other antipsychotics.9,11
Several studies have explored time to treatment discontinuation of
prescribed antipsychotics for early episode psychosis. These have
included pragmatic randomised prospective studies,10,12–15 natur-
alistic cohort studies16,17 and a prescription database study.18
Significant differences betweendiscontinuation times of thedifferent
medications were observed in at least half of these studies, but
consistent rankings of effectiveness across studies were not observed.
Most studies do not explore the breadth of oral antipsychotics
currently available. Heterogeneity of findings is not clearly explained
by study design although olanzapine is ranked at least of equal best
continuation rate in each of the randomised prospective studies
(despite it having themost associatedmetabolic adverse effects). This
mirrors the later stage illnessCATIEstudydatawhereolanzapinehad
the lowest discontinuation rate but the greatest weight gain and
dyslipidaemia.19
We aimed to further explore the aspects of antipsychotic
effectiveness in FEP between commonly used medications in a
large, naturalistic clinical sample across different UK FEP services,
using all-cause time to discontinuation as a comparator outcome.
Our hypothesis, based on these previous studies, was that
olanzapine would demonstrate a longer relative time to disconti-
nuation in comparison with other antipsychotic medications.
Method
Study design
A large sample retrospective, naturalistic cohort design was
adopted to compare the time to all-cause treatment discontinua-
tion of different antipsychotic drugs used in the treatment of an
FEP in an antipsychotic-naïve population, over 1 year (1 year of
treatment being a gold standard in clinical treatment).20
Participants
All patients accepted for treatment by the early intervention for
psychosis services at seven sites in the counties of Sussex and
Warwickshire and the City of Coventry, England, from 28
February 2009 to 28 February 2012 were recruited for the study.
The treatment sites covered the areas of Bognor Regis, Brighton
and Hove, Coventry, Eastbourne, Horsham, North Warwickshire,
South Warwickshire and Worthing and are a mixture of urban
and rural sites including areas with both low and high social
deprivation indices.
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Included patients met the criteria of ‘FEP’ in all seven services
during the period of data collection, as determined at clinical
interview with illness severity defined as a positive ‘CAARMS’
(comprehensive assessment of at-risk mental states) threshold for
psychosis or a score >4 on hallucinations and/or delusions and/or
>5 on conceptual disorganisation subscales of the PANSS (Positive
and Negative Syndrome Scale), and of duration at least 7 days. All
patients were aged between 14 and 35 years as per service criteria.
Patients were excluded from the study if psychotic symptoms were
due to a depressive or primary organic aetiology. Patients were also
excluded if they were under the care of the service for less than 1
year, or they were not prescribed antipsychotic medication at all
during their treatment with the service. Patients started on long-
acting injectable medications as their first treatment were also
excluded from the sample because of difficulty of comparison with
oral medications. Patients were not excluded if other psychotropic
drugs (non-antipsychotic mood stabilisers, benzodiazepines, anti-
depressants, etc.) were used in combination with an antipsychotic.
Those individuals for whom reliable data concerning type and
duration of treatment were not available were also excluded.
Clinicians would have commenced and managed treatment
following international and local guidelines for treating FEP
patients and using their own clinical experience in collaboration
with the views and attitudes of the patient and the patient’s
family. Similarly, treatment was ‘open label’ with flexible dosing.
Data procedures
For each patient, the case notes, prescription cards and electronic
records available were examined to determine the first antipsy-
chotic prescribed, the date of treatment onset and the point at
which the antipsychotic was discontinued. Raters were all
psychiatrists (all authors listed except C.I.J.), and the data entered
on a pre-designed form with variables defined.
Outcome measures
Discontinuation was defined as the first day of a 2-week or longer
interruption in treatment adherence as decided by author and
academic peer consensus. Dates of treatment discontinuation were
ascertained by careful scrutiny of recorded clinical notes. Where
only approximations were available (e.g. treatment stopped ‘a few
weeks ago’), prescribing clinicians were contacted to improve
precision. Standard dates were used when periods of the month
were referred to. Where greater clarity could not be sought,
estimates were made by agreement reached by a panel of three of
the researchers, or data were entered as ‘unavailable’ if this was
not possible. Where a cross-titration of medication was initiated,
the date of discontinuation was taken as the first day of the cross-
titration. If patients were lost to follow-up (e.g. disengaged from
treatment before completing a year of medication), they were
excluded from the cohort but included in an intention-to-treat
analysis.
All raters undertook an interrater reliability exercise. Records
of 10 patients were randomly chosen and a chronology of the
prescribing transcribed by the clinician who had initially rated the
case. The accuracy of this rating, as judged by the time to
discontinuation in days, was assessed based on these transcrip-
tions by all other raters.
The causes for treatment discontinuation were recorded for
analysis and comparison between antipsychotic cohorts. These
were divided into ‘clinician managed’ – where the clinician was
informed and the discontinuation was planned by the clinician –
and ‘patient managed’ – where the clinician was not informed.
Reasons for discontinuation were then categorised by the primary
reason for patient or clinician dissatisfaction with the medication
(such as lack of efficacy, adverse effects or poor adherence without
clear association with medication factors). Where adverse effects
were the main factor, these were also classified as sedation, sexual
dysfunction, extrapyramidal dysfunction, weight gain, agitation or
‘other’.21 In cases where more than one reason was given for
treatment attrition, two researchers determined a consensus rating
of the most important reason based on the clinical file, requesting
input from the prescribing clinician if possible or a third clinician
if necessary to reach majority consensus.
Statistical methods
Data from each group were analysed following intention-to-treat
principles. The median survival time was calculated for specified
medications, referring to the number of days when 50% of the
cohort had discontinued that treatment. The advantage of this
measurement is that it is not dependent on length of follow-up
time (some patients continuing treatment beyond 12 months) and
can be compared with median survival times from other studies
with different follow-up periods. ‘Mean time to patient disconti-
nuation’ is often used in studies but is dependent on discontinua-
tion rate, which is relative to the follow-up period used. Cox
proportional hazards regression analysis was conducted to deter-
mine the impact on time to discontinuation of antipsychotic type,
age, gender, duration of untreated psychosis (DUP; defined as the
time from date of psychotic symptom onset to the date of
medication commencement), clinical role of first prescriber and
region of initiation on the survival function. Data were analysed
using Stata version 14.1.
Ethics
Locality governance approval was attained for this study on the
basis of service evaluation examining how standard care is
delivered where decisions regarding the prescribing and adminis-
tering of treatment were made jointly by the clinician and patient.
Results
Study sample and baseline characteristics
Five hundred and ten patients met the inclusion criteria of FEP for
treatment by the early intervention services in this study, within
the designated time period. Fifty patients were excluded from this
study as per designed method, owing to not starting an oral
antipsychotic medication or relevant baseline data were lacking
(Fig. 1). Olanzapine, quetiapine, risperidone and aripiprazole were
the first-line treatments chosen for 97.8% of patients, comprising
40.2, 25.2, 19.1 and 13.3% of the sample, respectively. For 28
patients, follow-up data were not available due to disengagement
with services or leaving the locality (before 1 year of treatment or
until treatment was discontinued), resulting in a final analysis
sample of 427. No deaths of any cause were observed in available
data. The proportion of patients without follow-up data was
similar for the four antipsychotics, ranging from 3% for olanza-
pine to 9% for risperidone.
Baseline characteristics of the study sample are shown in
Table 1. The greatest proportion of the sample was male and had
antipsychotic medication initiated in a community v. an acute care
setting. Only 30% had medication initiated by early intervention
services. Median age, median DUP and role of prescriber were all
significantly different between the four most likely prescribed
antipsychotic medications (all P<0.001). Those prescribed olanza-
pine had a notably lower median DUP and were most likely to be
managed by acute care services (in-patient or community crisis
team) than other groups.
Comparison between baseline variables of included and
excluded cases revealed no significant difference between age,
Whale et al
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DUP, gender and prescriber role. A significant difference was
revealed between geographical areas, with more missing data in
Warwickshire than Sussex.
Interrater reliability
For the interrater reliability exercise, based on time to discontinua-
tion in days between the raters, the intra-class correlation coefficient
was very high (0.99) suggesting high reliability of ratings.
Time to discontinuation
In the whole cohort, 73.3% of patients discontinued their first
prescribed antipsychotic within 12 months. The all-cause rate of
discontinuation within 12months from initiation ofmedication and
median survival times by antipsychotic medication are shown in
Table 2. Although the ranking of lowest discontinuation rates and
longest time to discontinuation was risperidone, quetiapine, aripi-
prazole then olanzapine, both favouring risperidone, no statistically
significant differenceswere foundbetweenmedications.The survival
distribution curves of the four medications are plotted in Fig. 2.
Multivariable Cox regression analysis revealed no significant
association between medication type and time to discontinuation,
using olanzapine as the reference category as per our hypothesis
(Table 3). A significant effect of both DUP years (HR 0.87, 95% CI
0.77 to 0.98, P=0.028) and region of first prescription (Sussex v.
Warwickshire; HR 1.50, 95% CI 1.05 to 2.15, P=0.026) on survival
was demonstrated. The discontinuation rate was reduced by
0.0027% per week (or 13% per year) of DUP. Discontinuation
rate was 50% higher in Sussex v. Warwickshire. No significant
effect of age, gender or prescriber role was observed.
Overall, 60.2% (189/314) of patients discontinued treatment
aided by a clinician v. those stopping medication themselves
(Table 2). No significant difference was observed for this variable
between the four most commonly prescribed antipsychotic
medications (for Chi-squared test, P=0.13).
The primary reasons for discontinuation of each antipsychotic
group recorded by clinicians are shown in Fig. 3. Of all
discontinuations (excluding 66 missing values), 34.4% were
attributed to poor patient adherence (without clear attribution to
medication efficacy or adverse events), and this was the primary
reason given for patients discontinuing for all antipsychotic
groups. The next commonest whole group reason was poor
efficacy (20.5%).
After poor adherence, the magnitude of reasons for disconti-
nuation by drug (over 5% of the individual drug sample) was
ranked: for aripiprazole, poor efficacy joint with agitation/rest-
lessness, then extrapyramidal side-effects; for olanzapine, weight
gain joint with poor adherence, sedation and then poor efficacy;
for quetiapine, sedation, poor efficacy and then weight gain; and
for risperidone, poor efficacy, raised prolactin, sedation and then
weight gain. Relative proportions of these causes by drug are
shown in Fig. 3. Of note, olanzapine and risperidone had the
lowest rates of poor adherence.
Discussion
In a large naturalistic FEP cohort, we demonstrate a high rate of
all-cause discontinuation (whether switching to another
510 Patients accepted for 
first episode psychosis  
case-load
4 Prescribed depot 
antipsychotic
33 Reliable data not available
61 Aripiprazole
460 Prescribed antipsychotic 
in naturalistic clinic setting
13 Not prescribed 
antipsychotic
185 Olanzapine 116 Quetiapine 88 Risperidone 10 Other:
3 Amisulpride
1 Haloperidol
1 Chlorpromazine
5 Not documented 
5 Further 
data not 
available
6 Further 
data not 
available
9 Further 
data not 
available
8 Further 
data not 
available
Fig.1 Study recruitment ﬂow chart.
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medication or not) of the initially prescribed antipsychotic of
73.3% by 1 year. Four antipsychotics (aripiprazole, olanzapine,
quetiapine and risperidone) accounted for 97.8% of prescriptions
for first-line treatment of FEP. Risk of discontinuation was highest
in the first 3 months of treatment for all medications. Although
risperidone had a longer median time to discontinuation than
other medications, multivariable Cox regression analysis revealed
no significant effect of medication type on all-cause time to
discontinuation. Significant differences were observed between
prescribed medication groups for age, DUP and role of initiating
prescriber. Only DUP and geographical site had significant
influence on discontinuation. The most prevalent reason for
discontinuation was ‘poor patient adherence’, grouped as inde-
pendent of clearly associated adverse effects.
DUP has a consistently demonstrated effect on FEP outcome,
and a longer DUP may be explained by negative symptoms.22
Negative symptoms have an arguably poor response to currently
licensed antipsychotic medications,23 which may account for
earlier discontinuation in those with a longer DUP. Although
olanzapine did not have a significantly different discontinuation
rate from other medications, it appeared to be most used in acute
services, possibly a marker for a more severely unwell group. This
could explain olanzapine’s lower ranked median discontinuation
time, although prescriber role did not have significant effect in the
multivariable analysis. The olanzapine-exposed group also had a
shorter DUP than other medications but this did not positively
bias its comparative discontinuation rate. The significant effect of
region on discontinuation is unexpected and reasons are unclear
from this data set. The other difference observed between regions
was a larger missing data rate in Warwickshire, which does not
have obvious association with discontinuation time. Variables not
explored, such as ethnicity, may influence this effect of region.
Comparison with previous studies
In comparison with other studies that have described all-cause
medication discontinuation rates in FEP populations, our overall
rate was higher than reported in randomised studies (all-cause
discontinuation at 12 months for Kahn et al10 was 41.6%, McEvoy
et al12 70.3%, Crespo-Facorro et al14 58.6% and San et al15 64%).
The naturalistic follow-up study by Tiihonen et al described a
rapid early attrition with discontinuation rate of 54.3% at 30 days
(a much greater rate than we observed, although their sample was
post in-patient admission), and 92.5% at a mean follow-up of 2
years (direct comparison with our data not possible).16 Also
naturalistic, Liew et al described a 90% all-cause discontinuation
rate by 18 months, roughly 80% by 12 months (extrapolated from
published report).17 This implies that the boundaries of and
nature of patients recruited to a randomised study enhance
antipsychotic adherence in comparison with a naturalistic study.
It is also arguable that our sample, using FEP criteria rather than
Table 1 Characteristics of sample in total cohort and by medication group
Overall Aripiprazole Olanzapine Quetiapine Risperidone Othera Statistical test P
Age entering EIP
case-load (years)
Median 22.0 21.0 23.0 22.0 21.0 24.0 Kruskal–Wallis 0.0001
IQR 19.0–27.0 19.0–26.0 20.0–28.0 19–26.5 18.0–24.0 21.0–25.0
n 421 55 178 104 79 5
Duration of untreated
psychosis (weeks)
Median 5.0 8.6 3.0 6.1 8.6 26.0 Kruskal–Wallis 0.0007
IQR 1.0–22.3 2.7–23.1 1.0–11.7 1.3–30.0 2.0–48.6 7.9–26.9
n 384 45 165 97 72 5
Gender % male 65.1 55.4 67.6 62.6 68.8 80.0 Chi-squared 0.311
n male 278 31 121 67 55 4
n overall 427 56 179 107 80 5
Clinical role of
prescriber
Acute services% 43.0 37.5 59.0 28.3 31.3 33.3
Community (non-EIP)% 24.4 28.6 20.8 28.3 22.5 66.7
EIP% 30.3 32.1 17.4 41.5 43.8 0.0 Chi-squared <0.001
GP%a 2.4 1.8 2.8 1.9 2.5 0.0
n overall 423 56 178 106 80 3
Region % Sussex 78.5 76.8 82.7 80.4 72.5 0.0
n Sussex 335 43 148 86 58 0
% Warwickshire 21.6 23.2 17.3 19.6 27.5 100.0 Chi-squared 0.284
n Warwickshire 92 13 31 21 22 5
EIP, early intervention in psychosis; GP, general practitioner.
a. Excluded from comparisons/tests for association owing to low numbers.
Table 2 Discontinuation variables between medications within 12 months of initiation
Overall Aripiprazole Olanzapine Quetiapine Risperidone Othera Statistical test P
Discontinuation within
12 months
% 73.3 76.8 78.2 69.2 66.3 60.0
n 313 43 140 74 53 3 Chi-squared 0.136
n overall 427 56 179 107 80 5
Time to discontinuation
(days)
Median 75.0 73.0 70.0 77.0 87.0 28.0
IQR 36.0–154.0 35.0–176.0 41.5–145.5 30.0–145.0 30.0–165.0 10.0–37.0 Kruskal–Wallis 0.997
n overall 427 56 179 107 80 5
Clinician managed
discontinuation?
% yes 60.2 50.0 63.1 52.8 68.5 100.0
n yes 189 22 89 38 37 3 Chi-squared 0.133
n overall 314 44 141 72 54 3
a. Excluded from comparisons/tests for association owing to low numbers.
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specific ICD-10 or DSM-IV diagnoses, was less stringent for
inclusion, and possibly overall less severely unwell, with more
likelihood of remaining well after a single psychotic episode and
therefore more likely to discontinue medication.
Despite differences in ranking of order of rate of discontinua-
tion (and median discontinuation time), our finding of no
significant difference between commonly used medications on
the survival function in multivariable analysis is consistent with
previous studies. Kahn et al conducted a randomised, unblinded,
pragmatic study in an analysis sample of 498 patients.10 They
found relatively lower rates of all-cause discontinuation at 12
months for olanzapine (33%) than quetiapine (53%), amisulpride
(40%) and ziprasidone (45%) and a notably higher discontinua-
tion rate with haloperidol (72%). Survival analysis showed
significant differences when comparing all medications but no
significant difference was observed between olanzapine and
quetiapine.20 McEvoy et al randomised treatment to olanzapine,
quetiapine and risperidone in a patient sample with FEP, finding
no significant difference in all-cause discontinuation at 52 weeks
but a numerically lower rate with olanzapine (68.4, 70.9 and
71.4%, respectively).12 Crespo–Facorro et al followed up a sample
of 174 patients with first-episode non-affective schizophrenia
spectrum disorders, randomised to haloperidol, risperidone and
olanzapine, and although they found discontinuation rates at 1
year were significantly higher for haloperidol, the rates for
risperidone and olanzapine were not significantly different.14
This lack of difference was sustained by 3 years’ follow-up.24
Johnsen et al randomised 213 successive admissions with a wide
range of diagnosed psychotic disorders (including depressive and
drug-induced psychosis) at an emergency ward in Norway to four
commonly used antipsychotics.13 Included participants were not
clearly FEP however, with only 44% of participants being
antipsychotic naϊve. At 1-year follow-up, study dropout rates
were high, but by an intention-to-treat model, ranking of greatest
likelihood of continuation was quetiapine, olanzapine, ziprasidone
then risperidone, but not of different enough magnitude to render
significance.
In contrast with our results, Tiihonen et al followed up a
naturalistic cohort of first hospitalised patients for schizophrenia
and schizoaffective disorder (interpreted as a first episode of
schizophrenia) in Finland and found olanzapine was significantly
less likely to be discontinued within 30 days of discharge v.
risperidone and less associated with rehospitalisation than risper-
idone over a mean 2 years follow-up.16 In comparison, disconti-
nuation within 30 days was very similar for all medications in our
sample. Twelve-month discontinuation comparison was not
reported by Tiihonen et al and neither quetiapine nor aripiprazole
were commonly used.16 San et al randomised treatment with
haloperidol, olanzapine, risperidone, quetiapine and ziprasidone
to 114 antipsychotic-naive FEP patients. The lowest discontinua-
tion rate observed by 1 year was for olanzapine (40%), this being
significantly lower than for risperidone (64%) and quetiapine
(56.5%) but all lower than haloperidol and ziprasidone (both
>80%).15 In a further naturalistic first-episode schizophrenia
spectrum disorder study, Liew et al found significantly lower rates
of discontinuation of risperidone compared with haloperidol and
trifluoperazine in an Asian cohort (only risperidone was used
commonly in our sample).17 The median time to discontinuation
for risperidone was 69 days, shorter than we report.
Limitations and strengths
This study is one of the largest investigations reported of a real-
world cohort of FEP patients taking a range of commonly used
medications. It arguably reflects standard patients seen by early
psychosis services across the UK, including seven separate teams
with different geographical catchments (both urban and rural) and
notable ethnic variation. It is possible that variation from findings
of some previous studies15,16 reflects different patient populations.
Although it is possible that our results incorporate bias of
medication choice, due to the non-randomised nature of the
study, this is mitigated by the number of services and prescribing
doctors involved, the fact that none of the prescribers was aware
that discontinuation time would be used as a method to compare
medications and the non-significant effect of medication type on
the all-cause discontinuation. The interrater reliability as to date of
discontinuation was very high which suggests minimal rater bias.
A disadvantage of retrospective studies where case notes are
relied upon is the potential for information bias. Clinical records
have not been kept in a manner that was designed specifically for
this study, and the data we required were not always measured
and recorded in ways that were ideal. That said, there is only a
small amount of missing follow-up data for those prescribed an
antipsychotic (7%) but we cannot be sure that the people whose
data we could not locate did not have different discontinuation
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Fig. 2 Kaplan–Meier survival estimates for time to all-cause
treatment discontinuation by antipsychotic medication.
Table 3 Multivariable Cox regression analysis for time to all-
cause treatment discontinuation
Hazard ratio 95% CI P
Medication (olanzapine reference category)
Aripiprazole 1.06 0.72–1.57 0.756
Quetiapine 0.94 0.69–1.28 0.677
Risperidone 0.84 0.59–1.20 0.348
Age 1.02 0.99–1.04 0.156
DUP years 0.87 0.77–0.98 0.028
Gender
Male 1.06 0.82–1.36 0.652
Prescriber role (acute services reference category)
Community (non-EIP) 0.95 0.70–1.23 0.722
EIP 0.86 0.63–1.18 0.346
GP 1.22 0.56–2.64 0.613
Region
Sussex 1.50 1.05–2.15 0.026
EIP, early intervention in psychosis; GP, general practitioner.
327
Antipsychotic effectiveness in first-episode psychosis
rates. The age, gender and DUP of those with missing data were
not significantly different from the included cohort with full data
available. Although our raters demonstrated good interrater
reliability, the ratings on discontinuation are taken from the
clinical files and therefore rely on the accuracy of these files. We
were also not able to collect some information on possible
confounders such as ethnicity, specific diagnosis (not just FEP),
functional impairment and illness severity. We did not include a
variable related to medication dose owing to the differences
between medications and variation over time. All of the early
intervention teams used NICE guideline interventions and low-
dose medication strategies; three of the teams had a specific low-
dose FEP service protocol. This may bias particularly against
quetiapine due to its wide dosing flexibility and low dopamine D2
receptor affinity at lower doses. Further research in larger samples
to investigate treatment groups with smaller numbers (such as
aripiprazole in this study), and enable further subgroup analysis, is
warranted. The documented cause of discontinuation is arguably
the least reliable variable considered, with potential overlap of
variables and bias by preconceived clinician and patient attitudes
about the properties of a medication. This would require
prospective qualitative analysis to explore more clearly, particu-
larly in the ‘poor adherence’ coded group. Significant adverse
effects differentially associated with the medications studied, and
ranked by reported frequency, clearly reflect those from existing
literature however.3,21 Recruitment to earlier studies also may
influence patient and clinician attitude to medication with greater
recent publicity around metabolic issues with olanzapine v. other
medications.
We excluded individuals prescribed long-acting injectable
(depot) medication but the numbers of patients started on this as
a first treatment were small (n=4) as per usual current treatment for
FEP. The cohort has a low rate of individuals starting on other
antipsychotics such as amisulpride or older dopamine antagonists
and does not include other newer medications that have recently
been licenced in the UK (asenapine and lurasidone).
Clinical implications
This naturalistic study by multivariable analysis, adjusting for
confounding factors, assists in confirming the applicability of
findings from existing randomised studies to the wider clinical
setting. These studies build on efficacy studies to largely support a
lack of difference in effectiveness (as measured by all-cause time
to discontinuation) between commonly used antipsychotic medica-
tions in FEP. Most patients will discontinue their first antipsychotic
medication (for a variety of reasons) in the first year of treatment
however, and clinicians should expect this to be the norm rather
than the exception. Strategies to improve this should bemore widely
adopted, such as shared decision-making and insight-orientated
interventions.25 This is also clearly relevant beyond first episode
prescribing.26 Long-acting antipsychotic preparations, not explored
in this study, may also have a role in enhancing effectiveness in this
setting.27 Common adverse effects associated with discontinuing
specific medications, as highlighted by this study and others,21
should be a focus of discussion pre-treatment when deciding with
the patient which medication should be first prescribed.
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